Results 41 to 50 of about 74,737 (254)
Guillain‐Barré syndrome during SARS‐CoV‐2 pandemic: A case report and review of recent literature
Acute demyelinating inflammatory polyneuropathy (AIDP) is the most common type of Guillain‐Barré syndrome (GBS) in Europe, following several viral and bacterial infections.
Erika Scheidl +3 more
semanticscholar +1 more source
Background Beyond the typical respiratory symptoms associated with novel coronavirus, increasing evidence has been reported of the neurological manifestations affecting both the central and peripheral nervous systems.
Seyede Momeneh Mohammadi +3 more
doaj +1 more source
Neurological manifestations and neuro-invasive mechanisms of the severe acute respiratory syndrome coronavirus type 2 [PDF]
Background and purpose Infections with coronaviruses are not always confined to the respiratory tract and various neurological manifestations have been reported.
Boon, Paul +6 more
core +2 more sources
Guillain-Barre syndrome often requires administration in intensivecare unit but is associated with good prognosis. That usuallymeans partial or full regress of motor impairment. However,we found that many reconvalescents after Guillain-Barre syndromewere
A. A. Khoroshun +2 more
doaj +1 more source
Prevention strategies for COVID-19 transmission are at the forefront of healthcare paradigms worldwide, the main emphasis of which is vaccination. We present an interesting case of a 37-year-old man who, 3 weeks following his first dose of the chimpanzee
Shreena Patel +3 more
semanticscholar +1 more source
Secondary membranous nephropathy associated with guillain-barré syndrome. [PDF]
Membranous nephropathy (MN) is one of the most common causes of nephrotic syndrome (NS) in adults. It may be primary, usually mediated by IgG4 anti-phospholipase A2 autoantibodies or secondary to various other conditions.
Bell, Rodney +4 more
core +2 more sources
Guillain-Barré syndrome after COVID-19 vaccination
We report a case of Guillain-Barré syndrome (GBS) occurring soon after the first dose of Vaxzevria (previously known as COVID-19 vaccine AstraZeneca).
Norma McKean, Charmaine Chircop
semanticscholar +1 more source
Neuropathophysiological potential of Guillain-Barré syndrome anti-ganglioside-complex antibodies at mouse motor nerve terminals [PDF]
Objectives: Anti-ganglioside antibodies are present in approximately half of Guillain–Barré syndrome (GBS) patients. Recently, it has been shown that a considerable proportion of these patients has serum antibodies against antigenic epitopes formed by a
Goodfellow +22 more
core +1 more source
Guillain-Barré Syndrome with asystole requiring permanent pacemaker: a case report
Introduction Guillain-Barré syndrome is an acute demyelinating disorder of the peripheral nervous system that results from an aberrant immune response directed at peripheral nerves. Autonomic abnormalities in Guillain-Barré syndrome are usually transient
Patel Mehul B +5 more
doaj +1 more source
Guillain-Barre syndrome during COVID-19 pandemic: an overview of the reports
Similar to severe acute respiratory syndrome coronavirus (SARS-CoV) and Middle East respiratory syndrome coronavirus (MERS-CoV), the coronavirus disease 2019 (COVID-19) has neurological symptoms. COVID-19 patients have such clinical symptoms as headache,
K. Rahimi
semanticscholar +1 more source

